High-Dose Vitamin D Linked to Lower Disease Activity in CIS

‘Fabulous’ Research

During a question-and-answer session, delegates praised the study, with some describing it as “fantastic” or “fabulous.”

Addressing a query about why this study succeeded in showing the benefits of vitamin D while numerous previous studies did not, Dr. Thouvenot said it may be due to the longer duration or a design that was better powered to show differences.

Asked if researchers examined vitamin D blood levels during the study, Dr. Thouvenot said these measures are “ongoing.”

Responding to a question of whether high-dose vitamin D could be a lifelong treatment, he referred again to the “excellent” safety of the intervention. Not only is it well tolerated, but vitamin D benefits bones and the risk for hypercalcemia is low except perhaps for patients with tuberculosis or sarcoidosis, he said.

“When you exclude those patients, the safety is huge, so I don’t know why we should stop it once it’s started.”

This study was funded in part by the French Ministry of Health. Dr. Thouvenot reported no relevant disclosures.

A version of this article first appeared on Medscape.com.